Released May 14, 2018, after the close
10-Q filed May 14, 2018, 44 days after period end · 0000926617-18-000044
Q1 2018 · 10-Q
Revenue$649.00K$649.00K −10.6% vs Q1 2017−18.7% vs Q4 2017
Net Income-$2.85M-$2.85M N/M vs Q1 2017N/M vs Q4 2017
EPS Diluted-$0.05-$0.05 N/M vs Q1 2017no prior Q4 2017 on file
Gross Profit-$154,000N/M
Operating Income-$2,835,000N/M
Operating Cash Flow-$2,357,000N/M
Free Cash Flowderived-$2,381,000N/M
Margins · derived
Gross margin-23.7%−23.6 pt vs Q1 2017
Operating margin-436.8%−71.0 pt vs Q1 2017
Net margin-439.1%−71.0 pt vs Q1 2017
What the release said
The release
Same quarter
| Metric | Q1 2018 | Q1 2017 | Q1 2016 | Q1 2015 |
|---|---|---|---|---|
| Revenue | $649.00K | $726.00K | $505.00K | $951.00K |
| Net Income | -$2.85M | -$2.67M | -$4.90M | -$4.14M |
| EPS Diluted | -$0.05 | -$0.05 | -$0.09 | -$0.10 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aspira Women's Health Inc. · CIK 926617 · Engraved from SEC EDGAR